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Abstract
Objective : There are few lung function tests available to evaluate bronchial asthma in infants and 
toddlers. The objective of this study was to test the hypothesis that the measurement of exhaled 
carbon monoxide (eCO) levels is applicable to evaluate infants and toddlers with stable asthma and 
during acute asthma attack. 
Methods : A one-way valve breath sampling bag was developed to collect the exhaled air of infants 
and toddlers. A total of 483 infants (under 2 years) and toddlers (2-5 years) were studied ; 355 had 
an established diagnosis of asthma (182 suffering mild asthma attacks and 173 without active asth-
matic symptoms), 119 had upper respiratory infection (URI) including acute bronchitis, and 9 were 
healthy.
Results : In infants and toddlers, eCO levels of those with asthma attacks [median (interquartile 
range) = 2.0 (2.0-3.25) ppm, n=182] were significantly higher than those of subjects with asymp-
tomatic asthma [2.0 (1.0-2.0) ppm, n=173, P < 0.0001], URI [2.0 (1.0-3.0) ppm, n=119, P < 0.0001], 
and healthy children [1.0 (0.0-1.0) ppm, n=9, P < 0.0001]. In 75 children with asthma petit mal, 
eCO levels during asthma attacks [3.0 (2.0-4.0) ppm] significantly decreased after therapy [1.0 (1.0-
2.0) ppm, P < 0.0001]. In infants and toddlers with an established diagnosis of asthma (n=355), 
eCO cut-off >2 ppm discriminated asthma attack from an asymptomatic state with a sensitivity of 
95.6%, a specificity of 43.3%, and an area under the curve (AUC) of 0.71 (95% CI : 0.65-0.76, P < 
0.0001). In 401 infants and toddlers with some respiratory symptoms, of which 285 cases were fi-
nally diagnosed as asthma [eCO level = 2.0 (2.0-3.0) ppm] and 116 cases were not asthma [eCO lev-
el = 2.0 (1.0-3.0) ppm, P < 0.0001], eCO cut-off >3 ppm supported the final diagnosis of asthma 
with a sensitivity of 38.9%, a specificity of 74.1%, and AUC of 0.63 (95% CI : 0.56-0.69, P < 0.0001). 
Conclusion : The measurement of eCO by a novel method is applicable to evaluate asthmatic activ-
ity and treatment responsiveness, and to diagnose asthma in infants and toddlers.
Key words :  infants and toddlers, mild asthma attack, simple breath sampling method
Introduction 
Asthma is a chronic lung disorder characterized 
by airway inflammation1). The inducible form of 
heme oxygenase (HO)-1 is expressed in airway epi-
thelial cells2), endothelial cells3), and alveolar macro-
phages4). Carbon monoxide (CO) is produced en-
dogenously by HO-1, and is known to be present in 
a low concentration in the exhaled air of normal sub-
jects5,6).
Upregulation of HO-1 by oxidative stress and 
proinflammatory cytokines in the airways and lung 
parenchyma increases the levels of exhaled CO 
(eCO) in patients with inflammatory pulmonary dis-
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eases such as bronchiectasis, upper respiratory tract 
infection (URI), acute pneumonia, silicosis, and sea-
sonal allergic rhinitis7-13). Recently, eCO levels were 
shown to be elevated in adults4,6), and school-age, 
and preschool children14-16) with persistent asthma.
Our group has investigated the usefulness of 
eCO measurement in school- and preschool chil-
dren15,16). In infants and toddlers, however, measur-
ing the eCO concentrations of episodic asthma in 
acute asthma attacks or in stable conditions and for 
other respiratory diseases is not feasible using the 
conventional method17). We developed a simple 
sampling system, which allows the measurement of 
eCO concentration in infants and toddlers with asth-
ma with or without attacks or those with URI. We 
examined the hypothesis that eCO reflects disease 
status and treatment effects in infants and toddlers. 
Methods
Study design and subjects
Infants (aged under 2 years) and toddlers (aged 
2-5 years) with asthma, with or without attacks, 
those with URI including acute bronchitis, and 
healthy controls were recruited at Ohara Children’s 
Clinic, Fukushima, from June 2013 to December 
2016. We enrolled only infants and toddlers with 
mild asthma attack as classified by the Japanese 
Guideline for the Diagnosis and Treatment of Aller-
gic Diseases 2010 (JAGL 2010)18). 
Definition and diagnosis of asthma
Infantile asthma is defined as asthma affecting 
infants aged <2 years. A diagnosis of infantile 
asthma is clinically made if there are 3 or more epi-
sodes of marked expiratory wheezing, regardless of 
the presence of respiratory tract infection, consider-
ing family history, past history, serum IgE level, re-
sponse to β2 stimulant inhalation, and so forth18). 
Intermittent asthma is defined as occurrence of 
symptoms fewer than several times a year and only 
brief exacerbations18) in infants and toddlers with 
mild asthma attack. We measured serum IgE lev-
els in asthmatic subjects using a commercially avail-
able method. We followed these children to control 
their symptoms15). The criteria of mild asthma at-
tack included breathless wheezing (+/−), retraction 
(−) - (+), prolongation of expiration (−), supine 
posture (−), cyanosis (−) and SpO2 ≥ 96%. We fol-
lowed these infants and toddlers to control their 
symptoms. We defined asymptomatic asthma as a 
history of infrequent mild asthma without exacerba-
tions for at least 8 weeks before the study15,16). No 
asthma patients had any respiratory history other 
than asthma. We excluded children from the study 
whose parents were current smokers to avoid the 
influence of second-hand smoke on eCO concentra-
tion. 
This study was conducted in accordance with 
the Declaration of Helsinki, and was approved by the 
ethics committee of Fukushima Medical University 
(Number 1432) on May 28, 2012. Informed paren-
tal consent was documented in writing.
Collection of exhaled air and eCO measurement in in-
fants and toddlers
We used a breath-sampling bag (200 mL) with a 
one-way valve, which is usually used for the 13-C 
urea exhaled test (Otsuka Pharmaceutical, Tokyo, 
Japan)15). We cut the bottom two thirds of the bag 
and connected it with a polyvinyl bag (18 cm × 27 
cm × 2 cm, approximately 1 L in volume) to de-
crease the respiratory resistance (Fig. 1). 
After collecting exhaled air, the sampling bag 
was connected to a piCO+Smokerlyzer (Bedfont Sci-
entific Ltd. England) using the one-way valve release 
adaptor and manually expelled the air into the instru-
ment to measure eCO concentration (Fig. 2). The 
measurement range of the piCO+Smokerlyzer is 
0-150 ppm. The instrument was calibrated with a 
gaseous mixture containing 20 ppm CO according to 
the manufacturer’s instructions. We confirmed the 
background CO level in the clinic using a Fluke CO-
220 Carbon Monoxide Meter (Everett, WA, USA) to 
be 0 ppm. We measured eCO only once, because it 
was impossible to measure eCO more than once with 
infants and toddlers. 
Clinical managements of the patients
Patients were treated with combined inhalation 
therapy with salbutamol and sodium cromoglicate 
(SCG) according to guidelines for the treatment of 
mild asthma attack. The combination therapy con-
sisted of a mixture of either 0.1 mL (<1 year of age), 
0.2 mL (1-5 years of age) of 5 mg/mL aqueous solu-
tion of salbutamol and 2 mL of 1% aqueous solution 
of SCG, which was delivered for 3 min using a jet 
nebulizer19,20). SCG + salbutamol inhalation thera-
py was repeated a maximum of four times per day if 
symptoms persisted. Long-term asthma manage-
ment with anti-inflammatory drugs was performed 
following the JPGL 2012 guideline18). We also mea-
sured arterial oxygen saturation using pulse oxyme-
try (SpO2) with a pulse oxymeter11) simultaneously 
with measurement of eCO concentration to monitor 
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respiratory conditions in patients with an acute asth-
ma attack. We excluded subjects from the study 
whose respiratory conditions prevented complete 
filling of the sampling bags.
Statistical analysis
Numerical data are presented as median (inter-
quartile range). Numerical data were compared 
among groups using the Kruskal-Wallis test with 
Dunn’s multiple comparisons test or the Mann Whit-
ney test, as appropriate. Categorical data were 
compared among groups using a chi-squared test or 
Fisher’s exact test, as appropriate. Because the 
levels of eCO did not show the normal distribution 
assessed by the D’Agostino & Pearson omnibus nor-
mality test, eCO data were compared among groups 
using the Kruskal-Wallis test with Dunn’s multiple 
comparisons test or the Mann Whitney test, as ap-
propriate. Changes between eCO during asthma 
attacks and after treatment were analyzed using the 
Wilcoxon matched-pairs signed rank test. A value 
of P < 0.05 was considered significant. 
We analyzed eCO levels in infants and toddlers 
in 4 ways : 1) comparison of eCO levels among 
healthy infants and toddlers, those with URI, those 
diagnosed as asthma but asymptomatic at the time of 
the eCO measurement (asymptomatic asthma 
group), and those diagnosed as asthma and in mild 
attack at the time of the eCO measurement (asthma 
attack group) ; 2) comparison of eCO levels before 
and after the treatment in 75 infants and toddlers 
Figure 1. Breath sampling methods
 Left-upper square enclosed with a dotted line : conventional method to sample exhaled breath using a non-rebreathing 
valve.
 Right-upper square enclosed with a line and lower figure : per os breath sampling method.
Figure 2. eCO measurement of collected exhaled air
 After collecting exhaled air, the sampling bag was 
connected to the Pico Smokerlyzer using a one-
way valve release adaptor and manually pushed 
out inspired air into the instrument to measure 
eCO concentration.
 eCO, exhaled carbon monoxide.
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with asthma attack in whom both the eCO values 
were available ; 3) to test the ability of eCO to diag-
nose activity of asthma, we compared eCO values in 
the asymptomatic asthma group and the asthma at-
tack group and performed receiver operating charac-
teristics (ROC) analyses ; 4) to test the ability of 
eCO to detect infants and toddlers with a final diag-
nosis of asthma in those with any respiratory symp-
toms, we compared eCO values in those with any 
respiratory symptoms with a final diagnosis of asth-
ma (composed from the asthma attack group and 
part of the asymptomatic asthma group with any re-
spiratory symptoms not satisfying the criteria of 
asthma attack) and those with respiratory symptoms 
without the final diagnosis of asthma (URI group, 
excepting 3 cases without respiratory symptoms), 
and performed ROC analyses.
ROC analyses of eCO to discriminate disease 
activity and the final diagnosis of asthma were per-
formed to obtain the area under the curve (AUC). 
Cut-off values were determined to maximize the 
sum of the sensitivity and specificity. To assess in-
dependence of eCO to discriminate disease activity 
and the final diagnosis of asthma, multiple logistic 
regression analyses were performed with adjust-
ments by age in years, gender, and SpO2 values.
Results
Patient background and the eCO levels in asthma and 
other status
We enrolled a total of 355 infants and toddlers 
with asthma, in whom 182 had mild asthma attacks 
and 173 were asymptomatic. We also enrolled 119 
infants and toddlers with URI - including acute bron-
chitis - and 9 healthy infants. Sampling and eCO 
measurement were accomplished in all subjects.
Healthy infants and toddlers were younger than 
those in other groups (Table 1). Children in the 
asthmatic group were older than those in the URI 
group. As such, body weights in the asthmatic 
group were generally higher than in other groups. 
SpO2 of the asthma attack group was lower than oth-
er groups, however it was within the normal range, 
which indicated that the respiratory state of the 
present patients was not severely depressed. The 
infants and toddlers with asthma had been taking a 
disodium cromoglycate inhalation in ≈60%, and a 
leukotriene receptor antagonist in ≈90%, of both 
the asymptomatic asthma and asthma attack groups. 
The infants and toddlers in the asthma attack group 
had been taking an inhaled corticosteroid more often 
(10%) than those in the asymptomatic asthma group 
(3%, P = 0.0005).
The eCO level during asthma attacks in asth-
matic infants and toddlers [n = 182, median (inter-
quartile range) = 2.0 (2.0-3.25) ppm] was signifi-
cantly higher compared to healthy controls [n = 9, 
1.0 (0.0-1.0) ppm, P < 0.0001], URI [n = 119, 2.0 
(1.0-3.0) ppm, P < 0.0001] and those with asymp-
tomatic asthma [n = 173, 2.0 (1.0-2.0) ppm, P < 
0.0001] (Fig. 3). However, there were considerable 
overlaps in the eCO levels among the asthma attack, 
asymptomatic asthma, and URI groups (Fig. 
3). The infants and toddlers taking an inhaled cor-
ticosteroid tended to have a higher eCO level [2.0 
(1.0-4.75) ppm] than those not taking [2.0 (2.0-3.0), 
P = 0.53]. Neither taking a disodium cromoglycate 
inhalation nor a leukotriene receptor antagonist re-
lated with eCO levels. There were no gender dif-
ferences in the eCO levels within the subgroups 










Age (years)* 0.85 (0.78-0.86) 1.0 (0.7-1.9) 2.8 (2.2-3.6) 2.5 (2.0-3.4) <0.0001
Female, n (%) 3 (33) 43 (36) 40 (30) 61 (34) <0.0704
Body weight (kg)* 9.1 (8.5-9.3) 9.0 (8.4-10.8) 13.2 (12.0-14.4) 12.5 (11.0-14.0) <0.0001














Disodium cromoglycate inhalation nd nd 62% 63% <0.88
Leukotriene receptor antagonist nd nd 90% 91% <0.74
Inhaled corticosteroid nd nd  3% 10% <0.005
nd, not done ; URI, upper respiratory infection.
*, data are shown as median (interquartile range).
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(Table 2).
The eCO levels before and after the treatment of asth-
ma
We compared the eCO levels before and after 
treatment in 75 infants and toddlers with asthma at-
tack. The eCO levels during asthma attacks was 
elevated [3.0 (2.0-4.0) ppm] and significantly de-
creased after therapy [1.0 (1.0-2.0) ppm, P < 
0.0001 ; Fig. 4]. We re-examined the eCO levels 
2-3 days after the prescription of anti-inflammatory 
drugs, not just after the inhalation therapy on the 
same day.
The eCO levels by the activity of asthma
In the asthmatic infants and toddlers (n = 355), 
asymptomatic asthma (n = 173) had eCO of 2.0 (1.0-
2.0) ppm and asthma attack (n = 182) had eCO of 2.0 
(2.0-3.25) ppm (P < 0.0001) (Fig. 5A). eCO cut-off 
≥2 ppm discriminated asthma attack from asymp-
tomatic asthma with a sensitivity of 95.6%, a speci-
ficity of 43.3%, and an area under the curve (AUC) 
of 0.71 (95% CI : 0.65-0.76, P < 0.0001) (Fig. 
5B). In a multiple logistic regression analysis to di-
agnose asthma attack incorporating eCO levels, age, 
gender, and SpO2 values, only eCO levels indepen-
dently predicted asthma attack with an odds ratio of 
1.55 (95% CI 1.29-1.86) (P < 0.001).
The eCO levels to diagnose asthma in infants and tod-
dlers with respiratory symptoms
In 401 infants and toddlers reported to have re-
spiratory symptom, those with the final diagnosis of 
asthma had eCO of 2.0 (2.0-3.0) ppm (n = 285) and 
those without had eCO of 2.0 (1.0-3.0) ppm (n = 
116, P < 0.0001) (Fig. 6A). An eCO cut-off ≥3 
ppm discriminated those with a final diagnosis of 
asthma from those without, with a sensitivity of 
38.9%, a specificity of 74.1%, and AUC of 0.63 (95% 
CI : 0.56-0.69, P < 0.0001) (Fig. 6B). 
Because children with asthma were older than 
those without asthma in this study (Table 1), we 
performed a sensitivity analysis limiting the children 
with respiratory symptoms aged under 2 years. 
The eCO of children with asthma attack [2.0 (2.0-
3.0) ppm, n = 73] was still higher than those with 
URI [2.0 (1.0-3.0) ppm, n = 94, P < 0.0001]. An 
eCO cut-off >2 ppm discriminated children with 
asthma attack from those without asthma, with a 
sensitivity of 93.2%, a specificity of 40.4%, and AUC 
of 0.67 (95% CI : 0.58-0.75, P = 0.0002). In a mul-
tiple logistic regression analysis to detect a final di-
agnosis of asthma incorporating eCO levels, age, 
gender and SpO2 values, only age independently 
predicted a final diagnosis of asthma with an odds ra-
Table 2. eCO levels by gender
Female Male P
n Median (IQR) n Median (IQR)
Healthy  3 1.0 (0.0-1.0)   6 1.0 (0.0-1.0) 1.00
URI 43 2.0 (1.0-3.0)  76 2.0 (1.0-3.0) 0.56
Asymptomatic asthma 40 1.0 (1.0-2.0) 133 2.0 (1.0-3.0) 0.09
Asthmatic attack 61 2.0 (3.0-3.5) 121 2.0 (2.0-3.5) 0.74
eCO, exhaled carbon monoxide ; IQR, interquartile range ; URI, upper respi-
ratory infection.
Figure 3. eCO levels of infants and toddlers
 The eCO level during asthma attacks in asthmatic 
infants and toddlers [median (interquartile range) 
= 2.0 (2.0-3.25), n = 182] was significantly higher 
compared to that in healthy [eCO = 1.0 (0.0-1.0), 
n = 9], URI [2.0 (1.0-3.0), n = 119 including acute 
bronchitis] and asymptomatic asthma [2.0 (1.0-
2.0), n = 173].
 eCO, exhaled carbon monoxide ; URI, upper re-
spiratory infection.
 *, P<0.0001.
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tio of 7.21 (95% CI 4.53-11.49) (P < 0.001). Higher 
eCO levels had barely insignificant association with 
a final diagnosis of asthma (odds ratio and 95% CI 
were 1.22 and 0.98-1.53, P = 0.07).
Discussion
In this prospective observational study in a pri-
mary care setting, we showed that eCO measure-
ments were feasible in infants and toddlers, utilizing 
a combination of commercially available devices with 
some modifications. 
Fractional exhaled nitric oxide concentration 
(FeNO) is used in asthmatic infants and toddlers uni-
versally17,21-23). As far as we know, however, the in-
strument of FeNO measurement for infants and tod-
dlers is not readily available in Japan. We investigated 
measurement of eCO to reflect chronic airway in-
flammation of bronchial asthma using commercially 
available instruments15,16). Previous reports 
showed that airway inflammation leads to an in-
creased expression of HO-1 in the airway, resulting 
in an elevation of eCO in adult asthma patients4,6), 
and school-age and preschool children14-16) with per-
sistent asthma. Measurements of FeNO through a 
mask and nonrebreathing valve in infants and tod-
dlers was reported24). The ATS (American Thorac-
ic Society) in 2005 recommended off-line measure-
ment of FeNO using one tidal breath, but it was not 
standardized25-27).
At first, we tried to sample through the mask 
with rebreathing valve covering the nose and 
mouth. However, we observed that the rebreath-
ing valve interfered with breathing in infants and 
toddlers. Thus, we devised a per os sampling 
method, using a mask without a non-rebreathing 
valve, enabling the collection of eCO of in-
fants. Using this new technique, we applied eCO 
measurements in infants and toddlers. We showed 
that eCO of infants and toddlers with asthma attacks 
was higher than with those having asymptomatic 
asthma, URI, or good health. However, there were 
considerable overlaps of eCO levels among children 
Figure 4. eCO levels in patients with asthma attacks 
before and after therapy (n = 75) 
 eCO [median (interquartile range)] before therapy 
was 3.0 (2.0-4.0) ppm and eCO after therapy was 
1.0 (1.0-2.0) ppm (P < 0.0001).
 eCO, exhaled carbon monoxide.
Figure 5. ROC curve of eCO to evaluate asthma ac-
tivity in infants and toddlers diagnosed with asth-
ma
 A, distribution of eCO in asthmatic infants and tod-
dlers by presence or absence of asthma at-
tack. Dotted line indicates the cut-off ≥2 ppm, 
with a sensitivity of 95.6% and specificity of 
43.3%.
 B, the ROC curve to diagnose asthma attack from 
asymptomatic asthma in infants and toddlers diag-
nosed as asthma with an AUC of 0.71 (95% 
CI : 0.65-0.76, P < 0.0001).
 AUC, area under the curve ; CI, confidence 
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with asthma attacks, asymptomatic asthma, and 
URI. An eCO cut-off ≥2 ppm discriminated chil-
dren with asthma attack from those without attacks 
with a sensitivity of 95.6%, a specificity of 43.3%, 
and an area under the curve (AUC) of 0.71 (95% 
CI : 0.65-0.76, P < 0.0001). eCO levels indepen-
dently predicted asthma attack in a multiple logistic 
regression analysis adjusted for age, gender and 
SpO2 values. One may reasonably consider that 
symptoms are controlled with eCO lower than 2 
ppm in infants and toddlers known to have asth-
ma. Among patients who presented with any respi-
ratory symptoms, eCO cut-off ≥3 ppm discriminat-
ed children with a final diagnosis of asthma from 
those without, with a sensitivity of 38.9%, a specific-
ity of 74.1%, and AUC of 0.63 (95% CI : 0.56-0.69, 
P < 0.0001). The higher eCO level (≥3 ppm) may 
warrant further investigation to diagnose asthma in 
infants and toddlers. However, one should take 
care about patients’ age, considering the results of a 
multiple logistic regression analysis in which age 
was a stronger predictor of a final diagnosis of asth-
ma than eCO levels. Abd EL Khalek et al. reported 
that a cut-off value of 3 ppm for eCO was useful in 
distinguishing the exacerbation group from the qui-
escent group among children with chronic lung dis-
ease28). Further, several groups reported the use of 
a CO-Stat Meter (Natus Company, currently not 
available in Japan) to measure end-tidal carbon mon-
oxide (ETCO) for the diagnosis of bronchopulmona-
ry dysplasia in newborn infants at a cut-off value of 2 
ppm29-31). Elliott reported that single-breath FeNO 
(SB-FENO) concentration ≥30 ppb predicted per-
sistence of wheezing at age 3 years with a sensitivity 
of 77%, a specificity of 94%, and an area under the 
curve (AUC) of 0.86 (95% CI : 0.74-0.98)23).   These 
results and several previous reports support the 
clinical usefulness of eCO measurements in infants 
and toddlers in certain circumstances. 
FeNO is widely used and considered superior to 
eCO in the diagnosis as well as management of asth-
ma. However, there are several drawbacks in using 
FeNO. Currently, FeNO measurement requires 
forced exhalation which is impractical for infants and 
toddlers. The NiOX device to measure FeNO is 
600,000 yen + 2000 yen/test  k i t  in  Japan. 
PiCO+smokerlyzer is 118,000 yen. FeNO mea-
surement for32) infants and toddlers need Sievers® 
NOA 280 chemiluminescence analyser (GE Analyti-
cal Instruments ; Boulder, CO, USA) which is about 
7,100,000 yen in Japan and its breath sampling bag is 
3,300 yen. We used a disposable breath sampling 
bag used for the 13-C urea exhaled test (Otsuka 
Pharmaceutical, Tokyo, Japan)15) priced at 60 yen/
bag. The diagnostic ability of FeNO is superior to 
eCO ; however, it is too expensive and complicated 
to use in primary care clinics. eCO measurement 
has comparable diagnostic ability with better avail-
ability compared to FeNO and we believe that eCO 
measurement has its role in the management of 
asthmatic infants and toddlers in primary care prac-
tice or in low-resource settings33). However, our 
new method may be applicable to FeNO measure-
ments, resulting in improved availability and lower 
costs.
The elevated eCO concentrations during asth-
ma attacks were significantly decreased after thera-
A
B
Figure 6. eCO to diagnose asthma in infants and tod-
dlers with any respiratory symptoms
 A, distribution of eCO in infants and toddlers with 
any respiratory symptoms by diagnosis of asth-
ma. Dotted line indicates the cut-off 0≥3 ppm, 
with a sensitivity of 38.9% and specificity of 
74.1%.
 B, the ROC curve to diagnose asthma in infants 
and toddlers with any respiratory symptoms with 
an AUC of 0.63 (95% CI : 0.56-0.69, P < 0.0001).
 AUC, area under the curve ; CI, confidence 
interval ; eCO, exhaled carbon monoxide ; ROC, 
receiver operating characteristics.
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py in episodic asthma. We could not measure eCO 
just after inhalation combination therapy with salbu-
tamol and SCG, but measured it at 2-3 days after the 
prescription of anti-inflammatory drugs. The 
mechanism of the decline in eCO levels after asth-
matic therapy remains unclear, but it could be postu-
lated as follows : (1) as a potent bronchodilator, a 
combination therapy with salbutamol and SCG in-
creases airflow19), resulting in decrease in eCO 
concentrations ; and (2) anti-inflammatory drugs 
following the JPGL 2012 guideline18) step 1 may alle-
viate airway inflammation and decrease the produc-
tion of CO. 
SCG has not only anti-inflammatory actions but 
also potentiating actions of the smooth muscle-re-
laxing properties of salbutamol in the airway19). 
Silkoff et al. reported a flow dependency of NO con-
centrations in exhaled air34). We previously per-
formed expiratory peak flow measurements during 
mild asthma attacks in 4 of 22 patients (>8-year-old 
schoolchildren) and found a negative correlation be-
tween peak flow rate and eCO concentration16). In 
addition to the decrease of CO production from the 
airway, the restored airflow may be one of the mech-
anisms underlying decrease in the eCO levels after 
inhalation therapy with salbutamol and SCG, al-
though we could not obtain PEF data in infants and 
toddlers to support this assumption. It remains 
controversial, however, whether there is a simple 
flow dependency in the eCO concentration in pa-
tients with airway obstruction35,36). We should be 
prudent in interpreting the eCO levels in cases com-
plicated with allergic rhinitis, because the eCO lev-
els increase in this condition10,37).
Limitations
This study was conducted at a single communi-
ty pediatric clinic. The eCO results were not blind-
ed and might influence the diagnosis of asth-
ma. Relatively small numbers in this study 
preclude detailed sub-analyses of the results. 
Due to the nature of this observational study, 
characteristics of the groups were not well-con-
trolled. There was no significant gender difference 
in the eCO levels within subgroups (Table 2). The 
infants and toddlers in the asthma attack group had 
been taking an inhaled corticosteroid more often 
(Table 1) ; however, those taking an inhaled cortico-
steroid had higher eCO levels, which makes the pos-
sibility that controller medications might influence 
the eCO levels unlikely. The infants and toddlers 
diagnosed with asthma were older than those with-
out. However, sensitivity analysis limiting the children 
to those aged less than 2 years gave similar results, 
which support the usefulness of eCO measurements 
in infants and toddlers.
Conclusion
Measuring eCO is feasible in asthmatic infants 
and toddlers by modifying commercially available 
devices, and may be useful to assess the activity and 
treatment responsiveness in infants and toddlers 
with asthma, and to diagnose asthma in those with 
respiratory symptoms. 
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